Pharmacokinetic evaluation of pregabalin for the treatment of generalized anxiety disorder

References

• American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th revision (DSM-5). Washington (DC): American Psychiatric Press; 2013.
   Google Scholar
• Hoffman DL, Dukes EM, Wittchen HU. Human and economic burden of generalized anxiety disorder. Depress Anxiety. 2008;25(1):72–90.
   PubMed Web of Science ®Google Scholar
• Dell’Osso B, Camuri G, Benatti B, et al. Differences in latency to first pharmacological treatment (duration of untreated illness) in anxiety disorders: a study on patients with panic disorder, generalized anxiety disorder and obsessive-compulsive disorder. Early Interv Psychiatry. 2013;7(4):374–380.
   PubMed Web of Science ®Google Scholar
• Nutt DJ, Ballenger JC, Sheehan D, et al. Generalized anxiety disorder: comorbidity, comparative biology and treatment. Int J Neuropsychopharmacol. 2002;5(4):315–325.
   PubMed Web of Science ®Google Scholar
• Bandelow B, Sher L, Bunevicius R, et al. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiatry Clin Pract. 2012;16(2):77–84.
   PubMed Web of Science ®Google Scholar
• Reinhold JA, Rickels K. Pharmacological treatment for generalized anxiety disorder in adults: an update. Expert Opin Pharmacother. 2015;16(11):1669–1681.
   PubMed Web of Science ®Google Scholar
• Buoli M, Caldiroli A, Caletti E, et al. New approaches to the pharmacological management of generalized anxiety disorder. Expert Opin Pharmacother. 2013;14(2):175–184.
   PubMed Web of Science ®Google Scholar
• Maneeton N, Maneeton B, Woottiluk P, et al. Quetiapine monotherapy in acute treatment of generalized anxiety disorder: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2016;10:259–276.
   PubMed Web of Science ®Google Scholar
• Ammar G, Naja WJ, Pelissolo A. Treatment-resistant anxiety disorders: a literature review of drug therapy strategies. Encephale. 2015;41(3):260–265.
   PubMed Web of Science ®Google Scholar
• Altamura AC, Caldiroli A, Buoli M. Pharmacokinetic evaluation of fluvoxamine for the treatment of anxiety disorders. Expert Opin Drug Metab Toxicol. 2015;11(4):649–660.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Living with Fibromyalgia, Drugs Approved to Manage Pain; 2008 [cited 2011 Nov 6].
   Google Scholar
• Pande AC, Crockatt JG, Feltner DE, et al. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry. 2003;160(3):533–540.
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Kirkpatrick P. Pregabalin. Nat Rev Drug Discov. 2005;4(6):455–456.
   PubMed Web of Science ®Google Scholar
• PubChem, Open Chemistry Database. Compound summary for CID 5486971. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/5486971
   Google Scholar
• Marks DM, Patkar AA, Masand PS, et al. Does pregabalin have neuropsychotropic effects? A short perspective. Psychiatry Investig. 2009;6:55–58.
   PubMed Web of Science ®Google Scholar
• Bockbrader HN, Radulovic LL, Posvar EL, et al. Clinical pharmacokinetics of pregabalin in healthy volunteers. J Clin Pharmacol. 2010;50(8):941–950.
   PubMed Web of Science ®Google Scholar
• Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia. 2004;45(Suppl 6):13–18.
   PubMed Web of Science ®Google Scholar
• Chew ML, Plotka A, Alvey CW, et al. Pharmacokinetics of pregabalin controlled-release in healthy volunteers: effect of food in five single-dose, randomized, clinical pharmacology studies. Clin Drug Investig. 2014;34(9):617–626.
   PubMed Web of Science ®Google Scholar
• Tjandrawinata RR, Setiawati E, Putri RS, et al. Pharmacokinetic equivalence study of two formulations of the anticonvulsant pregabalin. Clin Pharmacol. 2015;7:69–75.
   PubMedGoogle Scholar
• Tassone DM, Boyce E, Guyer J, et al. Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. Clin Ther. 2007;29(1):26–48.
   PubMed Web of Science ®Google Scholar
• Pfizer Limited. Lyrica: EU summary of product characteristics. 2013 [cited 2014 Feb 26]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000546/WC500046602.pdf
   Google Scholar
• Corrigan BW, Pool WF, Posvar EL. Metabolic disposition of pregabalin in healthy volunteers [abstract no. PI-68]. Clin Pharmacol Ther. 2001;69:P18.
   Web of Science ®Google Scholar
• Frampton JE. Pregabalin: a review of its use in adults with generalized anxiety disorder. CNS Drugs. 2014;28(9):835–854.
   PubMed Web of Science ®Google Scholar
• Randinitis EJ, Posvar EL, Alvey CW, et al. Pharmacokinetics of pregabalin in subjects with various degrees of renal function. J Clin Pharmacol. 2003;43(3):277–283.
   PubMed Web of Science ®Google Scholar
• Spigset O, Westin AA. Detection times of pregabalin in urine after illicit use: when should a positive specimen be considered a new intake?. Ther Drug Monit. 2013;35(1):137–140.
   PubMed Web of Science ®Google Scholar
• Shoji S, Suzuki M, Tomono Y, et al. Population pharmacokinetics of pregabalin in healthy subjects and patients with post-herpetic neuralgia or diabetic peripheral neuropathy. Br J Clin Pharmacol. 2011;72(1):63–76.
   PubMed Web of Science ®Google Scholar
• Bockbrader HN, Burger P, Knapp L, et al. Population pharmacokinetics of pregabalin in healthy subjects and patients with chronic pain or partial seizures. Epilepsia. 2011;52(2):248–257.
   PubMed Web of Science ®Google Scholar
• Mann D, Liu J, Chew ML, et al. Safety, tolerability, and pharmacokinetics of pregabalin in children with refractory partial seizures: a phase 1, randomized controlled study. Epilepsia. 2014;55(12):1934–1943.
   PubMed Web of Science ®Google Scholar
• Italiano D, Perucca E. Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age: an update. Clin Pharmacokinet. 2013;52(8):627–645.
   PubMed Web of Science ®Google Scholar
• Johannessen Landmark C, Beiske G, Baftiu A, et al. Experience from therapeutic drug monitoring and gender aspects of gabapentin and pregabalin in clinical practice. Seizure. 2015;28:88–91.
   PubMed Web of Science ®Google Scholar
• Winterfeld U, Merlob P, Baud D, et al. Pregnancy outcome following maternal exposure to pregabalin may call for concern. Neurology. 2016;86(24):2251–2257.
   PubMed Web of Science ®Google Scholar
• Davanzo R, Dal Bo S, Bua J, et al. Antiepileptic drugs and breastfeeding. Ital J Pediatr. 2013;39:50.
   PubMed Web of Science ®Google Scholar
• Lockwood PA, Pauer L, Scavone JM, et al. The pharmacokinetics of pregabalin in breast milk, plasma, and urine of healthy postpartum women. J Hum Lact. 2016. DOI: 10.1177/0890334415626148. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Kasper S, Iglesias-García C, Schweizer E, et al. Pregabalin long-term treatment and assessment of discontinuation in patients with generalized anxiety disorder. Int J Neuropsychopharmacol. 2014;17(5):685–695.
   PubMed Web of Science ®Google Scholar
• Rickels K, Shiovitz TM, Ramey TS, et al. Adjunctive therapy with pregabalin in generalized anxiety disorder patients with partial response to SSRI or SNRI treatment. Int Clin Psychopharmacol. 2012;27(3):142–150.
   PubMed Web of Science ®Google Scholar
• Hadley SJ, Mandel FS, Schweizer E. Switching from long-term benzodiazepine therapy to pregabalin in patients with generalized anxiety disorder: a double-blind, placebo-controlled trial. J Psychopharmacol. 2012;26(4):461–470.
   PubMed Web of Science ®Google Scholar
• Kasper S, Herman B, Nivoli G, et al. Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial. Int Clin Psychopharmacol. 2009;24(2):87–96.
   PubMed Web of Science ®Google Scholar
• Feltner D, Wittchen HU, Kavoussi R, et al. Long-term efficacy of pregabalin in generalized anxiety disorder. Int Clin Psychopharmacol. 2008;23(1):18–28.
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Tobias K, Zornberg GL, et al. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry. 2006;67(5):771–782.
   PubMed Web of Science ®Google Scholar
• Rickels K, Pollack MH, Feltner DE, et al. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry. 2005;62(9):1022–1030.
   PubMed Web of Science ®Google Scholar
• Pohl RB, Feltner DE, Fieve RR, et al. Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing. J Clin Psychopharmacol. 2005;25(2):151–158.
   PubMed Web of Science ®Google Scholar
• Feltner DE, Crockatt JG, Dubovsky SJ, et al. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol. 2003;23(3):240–249.
   PubMed Web of Science ®Google Scholar
• Montgomery S, Emir B, Haswell H, et al. Long-term treatment of anxiety disorders with pregabalin: a 1 year open-label study of safety and tolerability. Curr Med Res Opin. 2013;29(10):1223–1230.
   PubMed Web of Science ®Google Scholar
• Cvjetkovic-Bosnjak M, Soldatovic-Stajic B, Babovic SS, et al. Pregabalin versus sertraline in generalized anxiety disorder. An open label study. Eur Rev Med Pharmacol Sci. 2015;19(11):2120–2124.
   PubMed Web of Science ®Google Scholar
• Olivares JM, Álvarez E, Carrasco JL, et al. Pregabalin for the treatment of patients with generalized anxiety disorder with inadequate treatment response to antidepressants and severe depressive symptoms. Int Clin Psychopharmacol. 2015;30(5):265–271.
   PubMed Web of Science ®Google Scholar
• Álvarez E, Olivares JM, Carrasco JL, et al. Clinical and economic outcomes of adjunctive therapy with pregabalin or usual care in generalized anxiety disorder patients with partial response to selective serotonin reuptake inhibitors. Ann Gen Psychiatry. 2015;14(1):2.
   PubMed Web of Science ®Google Scholar
• Karaiskos D, Pappa D, Tzavellas E, et al. Pregabalin augmentation of antidepressants in older patients with comorbid depression and generalized anxiety disorder-an open-label study. Int J Geriatr Psychiatry. 2013;28(1):100–105.
   PubMed Web of Science ®Google Scholar
• Martinotti G, Lupi M, Sarchione F, et al. The potential of pregabalin in neurology, psychiatry and addiction: a qualitative overview. Curr Pharm Des. 2013;19(35):6367–6374.
   PubMed Web of Science ®Google Scholar
• Baldwin DS, Den Boer JA, Lyndon G, et al. Efficacy and safety of pregabalin in generalised anxiety disorder: a critical review of the literature. J Psychopharmacol. 2015;29(10):1047–1060.
   PubMed Web of Science ®Google Scholar
• Generoso MB, Trevizol AP, Kasper S, et al. Pregabalin for generalized anxiety disorder: an updated systematic review and meta-analysis. Int Clin Psychopharmacol. 2017;32(1):49–55.
   PubMed Web of Science ®Google Scholar
• Dobrea C, Buoli M, Arici C, et al. Tolerability and use in co-administration of pregabalin in affective patients: a 6-month prospective naturalistic study. Expert Opin Drug Saf. 2012;11(6):893–899.
   PubMed Web of Science ®Google Scholar
• Chen B, Choi H, Hirsch LJ, et al. Cosmetic side effects of antiepileptic drugs in adults with epilepsy. Epilepsy Behav. 2015;42:129–137.
   PubMed Web of Science ®Google Scholar
• Javed A, Cohen B, Detyniecki K, et al. Rates and predictors of patient-reported cognitive side effects of antiepileptic drugs: an extended follow-up. Seizure. 2015;29:34–40.
   PubMed Web of Science ®Google Scholar
• Rossetti AO, Jeckelmann S, Novy J, et al. Levetiracetam and pregabalin for antiepileptic monotherapy in patients with primary brain tumors. A phase II randomized study. Neuro Oncol. 2014;16(4):584–588.
   PubMed Web of Science ®Google Scholar
• Modur PN, Milteer WE. Adjunctive pregabalin therapy in mentally retarded, developmentally delayed patients with epilepsy. Epilepsy Behav. 2008;13(3):554–556.
   PubMed Web of Science ®Google Scholar
• Huber B, Bocchicchio M, Feuerbaum E, et al. Efficacy and tolerability of pregabalin in patients with difficult-to-treat epilepsy and intellectual disability. Epilepsy Behav. 2008;13(2):397–401.
   PubMed Web of Science ®Google Scholar
• Parsons B, Sanin L, Yang R, et al. Efficacy and safety of pregabalin in patients with spinal cord injury: a pooled analysis. Curr Med Res Opin. 2013;29(12):1675–1683.
   PubMed Web of Science ®Google Scholar
• Irving G, Tanenberg RJ, Raskin J, et al. Comparative safety and tolerability of duloxetine vs. pregabalin vs. duloxetine plus gabapentin in patients with diabetic peripheral neuropathic pain. Int J Clin Pract. 2014;68(9):1130–1140.
   PubMed Web of Science ®Google Scholar
• Freeman R, Durso-Decruz E, Emir B. Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. Diabetes Care. 2008;31(7):1448–1454.
   PubMed Web of Science ®Google Scholar
• Freynhagen R, Serpell M, Emir B, et al. A comprehensive drug safety evaluation of pregabalin in peripheral neuropathic pain. Pain Pract. 2015;15(1):47–57.
   PubMed Web of Science ®Google Scholar
• Baron R, Martin-Mola E, Müller M, et al. Effectiveness and safety of tapentadol prolonged release (pr) versus a combination of tapentadol pr and pregabalin for the management of severe, chronic low back pain with a neuropathic component: a randomized, double-blind, phase 3b study. Pain Pract. 2015;15(5):455–470.
   PubMed Web of Science ®Google Scholar
• Dauri M, Lazzari M, Casali M, et al. Long-term efficacy of OROS® hydromorphone combined with pregabalin for chronic non-cancer neuropathic pain. Clin Drug Investig. 2014;34(5):309–316.
   PubMed Web of Science ®Google Scholar
• Courtois F, Borrey D, Haufroid V, et al. Pregabalin-associated myoclonic encephalopathy without evidence of drug accumulation in a patient with acute renal failure. Indian J Nephrol. 2014;24(1):48–50.
   PubMedGoogle Scholar
• Smith TL, Baldwin A, Cunningham LL Jr, et al. Rash associated with pregabalin use. Ann Pharmacother. 2008;42(12):1899–1902.
   PubMed Web of Science ®Google Scholar
• Halaby A, Kassm SA, Naja WJ. Pregabalin dependence: a case report. Curr Drug Saf. 2015;10(2):184–186.
   PubMedGoogle Scholar
• Aldemir E, Altıntoprak AE, Coşkunol H. Pregabalin dependence: a case report. Turk Psikiyatri Derg. 2015;26(3):217–220.
   PubMed Web of Science ®Google Scholar
• Gahr M, Franke B, Freudenmann RW, et al. Concerns about pregabalin: further experience with its potential of causing addictive behaviors. J Addict Med. 2013;7(2):147–149.
   PubMed Web of Science ®Google Scholar
• Schjerning O, Pottegård A, Damkier P, et al. Use of Pregabalin - A nationwide pharmacoepidemiological drug utilization study with focus on abuse potential. Pharmacopsychiatry. 2016;49(4):155–161.
   PubMed Web of Science ®Google Scholar
• Wood DM, Berry DJ, Glover G, et al. Significant pregabalin toxicity managed with supportive care alone. J Med Toxicol. 2010;6(4):435–437.
   PubMedGoogle Scholar
• Bockbrader HN, Burger P, Knapp L. Pregabalin effect on steady-state pharmacokinetics of carbamazepine, lamotrigine, phenobarbital, phenytoin, topiramate, valproate, and tiagabine. Epilepsia. 2011;52(2):405–409.
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Wilson EA, Wesche DL, et al. Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy. Epilepsia. 2005;46(9):1407–1413.
   PubMed Web of Science ®Google Scholar
• Bockbrader HN, Budhwani MN, Wesche DL. Gabapentin to pregabalin therapy transition: a pharmacokinetic simulation. Am J Ther. 2013;20(1):32–36.
   PubMed Web of Science ®Google Scholar
• Harden CL, Leppik I. Optimizing therapy of seizures in women who use oral contraceptives. Neurology. 2006;67(12 Suppl 4):S56–8.
   PubMed Web of Science ®Google Scholar
• Zacny JP, Paice JA, Coalson DW. Subjective, psychomotor, and physiological effects of pregabalin alone and in combination with oxycodone in healthy volunteers. Pharmacol Biochem Behav. 2012;100(3):560–565.
   PubMed Web of Science ®Google Scholar
• Chew ML, Plotka A, Alvey CW, et al. Effect of the gastrointestinal prokinetic agent erythromycin on the pharmacokinetics of pregabalin controlled-release in healthy individuals: a phase I, randomized crossover trial. Clin Drug Investig. 2015;35(5):299–305.
   PubMed Web of Science ®Google Scholar
• Gahr M, Schmid MM, Schönfeldt-Lecuona C. Pregabalin-associated elevation of clozapine serum levels. Pharmacopsychiatry. 2012;45(7):297–299.
   PubMed Web of Science ®Google Scholar
• Bandelow B, Wedekind D, Leon T. Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention. Expert Rev Neurother. 2007;7(7):769–781.
   PubMedGoogle Scholar
• Baldwin DS, Allgulander C, Bandelow B, et al. An international survey of reported prescribing practice in the treatment of patients with generalised anxiety disorder. World J Biol Psychiatry. 2012;13(7):510–516.
   PubMed Web of Science ®Google Scholar
• Stump P. Pregabalin–profile of efficacy and tolerability in neuropathic pain. Drugs Today (Barc). 2009;45(SupplC):19–27.
   PubMedGoogle Scholar
• Sáiz Martínez PA, Jimenez Treviño L, Díaz Mesa EM, et al. Dual diagnosis in anxiety disorders: pharmacologic treatment recommendations. Adicciones. 2014;26(3):254–274.
   PubMed Web of Science ®Google Scholar
• Boschen MJ. Pregabalin: dose-response relationship in generalized anxiety disorder. Pharmacopsychiatry. 2012;45(2):51–56.
   PubMed Web of Science ®Google Scholar
• Silva Miguel L, Silva Miguel N, Inês M. A cost-utility analysis of pregabalin versus venlafaxine XR in the treatment of generalized anxiety disorder in Portugal. Cost Eff Resour Alloc. 2013;11(1):8.
   PubMedGoogle Scholar
• De Salas-Cansado M, Olivares JM, Alvarez E, et al. Pregabalin versus SSRIs and SNRIs in benzodiazepine-refractory outpatients with generalized anxiety disorder: a post hoc cost-effectiveness analysis in usual medical practice in Spain. Clinicoecon Outcomes Res. 2012;4:157–168.
   PubMedGoogle Scholar
• Vera-Llonch M, Dukes E, Rejas J, et al. Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective. Eur J Health Econ. 2010;11(1):35–44.
   PubMed Web of Science ®Google Scholar
• Carrasco JL, Álvarez E, Olivares JM, et al. A comparative cost-analysis of initiating pregabalin or SSRI/SNRI therapy in benzodiazepine-resistant patients with generalized anxiety disorder in Spain. Actas Esp Psiquiatr. 2013;41(3):164–174.
   PubMed Web of Science ®Google Scholar
• Guglielmo R, Martinotti G, Clerici M, et al. Pregabalin for alcohol dependence: a critical review of the literature. Adv Ther. 2012;29(11):947–957.
   PubMed Web of Science ®Google Scholar
• Freynhagen R, Backonja M, Schug S, et al. Pregabalin for the treatment of drug and alcohol withdrawal symptoms: a comprehensive review. CNS Drugs. 2016;30(12):1191–1200.
   PubMed Web of Science ®Google Scholar
• Lim L, Goh J, Chan YH, et al. Attitudes toward utility, effects and side effects of treatment for anxiety and depression. Australas Psychiatry. 2016;24(6):556–560.
   PubMed Web of Science ®Google Scholar
• Bellou V, Belbasis L, Tzoulaki I, et al. Systematic evaluation of the associations between environmental risk factors and dementia: an umbrella review of systematic reviews and meta-analyses. Alzheimers Dement. 2016. DOI:10.1016/j.jalz.2016.07.152
   PubMedGoogle Scholar
• Altamura AC, Serati M, Buoli M, et al. Augmentative quetiapine in partial/nonresponders with generalized anxiety disorder: a randomized, placebo-controlled study. Int Clin Psychopharmacol. 2011;26(4):201–205.
   PubMed Web of Science ®Google Scholar